


## Avatrombopag maleate

Cat. No.:	HY-13463A
CAS No.:	677007-74-8
Molecular Formula:	C <sub>33</sub> H <sub>38</sub> Cl <sub>2</sub> N <sub>6</sub> O <sub>7</sub> S <sub>2</sub>
Molecular Weight:	765.73
Target:	Thrombopoietin Receptor
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC<sub>50</sub>=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A<sup>[1][2][3]</sup>.

### CUSTOMER VALIDATION

- J Clin Invest. 2022 Jan 27;e149856.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Fukushima-Shintani M, et al. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. *Eur J Haematol.* 2009;82(4):247-254.
- [2]. Xu H, et al. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. *Expert Rev Clin Pharmacol.* 2019;12(9):859-865.
- [3]. Nomoto M, Zamora CA, Schuck E, et al. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs. *Br J Clin Pharmacol.* 2018;84(5):952-960.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA